5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology
PubMed 32279398 · doi:10.1111/dth.13379
What was done
A review summarizing the pharmacological mechanisms, comparative efficacy, and safety profile of the 5-alpha reductase inhibitors finasteride and dutasteride in the treatment of androgenetic alopecia.
What was found
No numerical data or specific statistics are reported in the abstract. The authors state qualitatively that dutasteride has higher potency and superior efficacy compared to finasteride, with a comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
Why it matters
This review synthesizes comparative clinical rationale for dual versus single 5-alpha reductase inhibition in androgenetic alopecia management.
Limits
The abstract reports no search methodology, number of included studies, sample sizes, or quantitative risk estimates. As a narrative review, it carries inherent risks of study selection bias.
Cited by
- supports Dihydrotestosterone (DHT) is the active metabolite of testosterone that causes male-pattern hair loss.